Selected research
Industry Research
Non-Invasive Prenatal Screening (NIPS) Industry Research Report 2026
Market perspective
The global Non-Invasive Prenatal Screening (NIPS) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Non-Invasive Prenatal Screening (NIPS) market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Non-Invasive Prenatal Screening (NIPS) market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Non-Invasive Prenatal Screening (NIPS) market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Non-Invasive Prenatal Screening (NIPS) include Revvity, Quest Diagnostics, MedGenome, Mayo Clinic Laboratories, SYNLAB, Veritas Genetics, GGA, Cordlife and BGI Genomics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Non-Invasive Prenatal Screening (NIPS) market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Non-Invasive Prenatal Screening (NIPS).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Non-Invasive Prenatal Screening (NIPS) Market by Company
Revvity
Quest Diagnostics
MedGenome
Mayo Clinic Laboratories
SYNLAB
Veritas Genetics
GGA
Cordlife
BGI Genomics
Berry Genomics
Annaroad
Genesky
Weihansi Biomedical Technology
Non-Invasive Prenatal Screening (NIPS) Segment by Type
Screening in Uncomplicated Pregnancies
Screening in High-Risk Pregnancies
Others
Non-Invasive Prenatal Screening (NIPS) Segment by Application
Public Hospitals
Private Hospitals
Non-Invasive Prenatal Screening (NIPS) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-Invasive Prenatal Screening (NIPS) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Non-Invasive Prenatal Screening (NIPS) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-Invasive Prenatal Screening (NIPS).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Non-Invasive Prenatal Screening (NIPS) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Screening in Uncomplicated Pregnancies
- Screening in High-Risk Pregnancies
- Others
Applications
- Public Hospitals
- Private Hospitals
Companies covered
- Revvity
- Quest Diagnostics
- MedGenome
- Mayo Clinic Laboratories
- SYNLAB
- Veritas Genetics
- GGA
- Cordlife
- BGI Genomics
- Berry Genomics
- Annaroad
- Genesky
- Weihansi Biomedical Technology
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Non-Invasive Prenatal Screening (NIPS) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Screening in Uncomplicated Pregnancies
- 2.2.3 Screening in High-Risk Pregnancies
- 2.2.4 Others
- 2.3 Non-Invasive Prenatal Screening (NIPS) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Public Hospitals
- 2.3.3 Private Hospitals
- 2.4 Assumptions and Limitations
3 Non-Invasive Prenatal Screening (NIPS) Breakdown Data by Type
- 3.1 Global Non-Invasive Prenatal Screening (NIPS) Historic Market Size by Type (2021-2026)
- 3.2 Global Non-Invasive Prenatal Screening (NIPS) Forecasted Market Size by Type (2027-2032)
4 Non-Invasive Prenatal Screening (NIPS) Breakdown Data by Application
- 4.1 Global Non-Invasive Prenatal Screening (NIPS) Historic Market Size by Application (2021-2026)
- 4.2 Global Non-Invasive Prenatal Screening (NIPS) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Non-Invasive Prenatal Screening (NIPS) Market Perspective (2021-2032)
- 5.2 Global Non-Invasive Prenatal Screening (NIPS) Growth Trends by Region
- 5.2.1 Global Non-Invasive Prenatal Screening (NIPS) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Non-Invasive Prenatal Screening (NIPS) Historic Market Size by Region (2021-2026)
- 5.2.3 Non-Invasive Prenatal Screening (NIPS) Forecasted Market Size by Region (2027-2032)
- 5.3 Non-Invasive Prenatal Screening (NIPS) Market Dynamics
- 5.3.1 Non-Invasive Prenatal Screening (NIPS) Industry Trends
- 5.3.2 Non-Invasive Prenatal Screening (NIPS) Market Drivers
- 5.3.3 Non-Invasive Prenatal Screening (NIPS) Market Challenges
- 5.3.4 Non-Invasive Prenatal Screening (NIPS) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Non-Invasive Prenatal Screening (NIPS) Players by Revenue
- 6.1.1 Global Top Non-Invasive Prenatal Screening (NIPS) Players by Revenue (2021-2026)
- 6.1.2 Global Non-Invasive Prenatal Screening (NIPS) Revenue Market Share by Players (2021-2026)
- 6.2 Global Non-Invasive Prenatal Screening (NIPS) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Non-Invasive Prenatal Screening (NIPS) Head Office and Area Served
- 6.4 Global Non-Invasive Prenatal Screening (NIPS) Players, Product Type & Application
- 6.5 Global Non-Invasive Prenatal Screening (NIPS) Manufacturers Established Date
- 6.6 Global Non-Invasive Prenatal Screening (NIPS) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Non-Invasive Prenatal Screening (NIPS) Market Size (2021-2032)
- 7.2 North America Non-Invasive Prenatal Screening (NIPS) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Non-Invasive Prenatal Screening (NIPS) Market Size by Country (2021-2026)
- 7.4 North America Non-Invasive Prenatal Screening (NIPS) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Non-Invasive Prenatal Screening (NIPS) Market Size (2021-2032)
- 8.2 Europe Non-Invasive Prenatal Screening (NIPS) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Non-Invasive Prenatal Screening (NIPS) Market Size by Country (2021-2026)
- 8.4 Europe Non-Invasive Prenatal Screening (NIPS) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Non-Invasive Prenatal Screening (NIPS) Market Size (2021-2032)
- 9.2 Asia-Pacific Non-Invasive Prenatal Screening (NIPS) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Non-Invasive Prenatal Screening (NIPS) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Non-Invasive Prenatal Screening (NIPS) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Non-Invasive Prenatal Screening (NIPS) Market Size (2021-2032)
- 10.2 South America Non-Invasive Prenatal Screening (NIPS) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Non-Invasive Prenatal Screening (NIPS) Market Size by Country (2021-2026)
- 10.4 South America Non-Invasive Prenatal Screening (NIPS) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Non-Invasive Prenatal Screening (NIPS) Market Size (2021-2032)
- 11.2 Middle East & Africa Non-Invasive Prenatal Screening (NIPS) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Non-Invasive Prenatal Screening (NIPS) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Non-Invasive Prenatal Screening (NIPS) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Revvity
- 12.1.1 Revvity Company Information
- 12.1.2 Revvity Business Overview
- 12.1.3 Revvity Revenue in Non-Invasive Prenatal Screening (NIPS) Business (2021-2026)
- 12.1.4 Revvity Non-Invasive Prenatal Screening (NIPS) Product Portfolio
- 12.1.5 Revvity Recent Developments
- 12.2 Quest Diagnostics
- 12.2.1 Quest Diagnostics Company Information
- 12.2.2 Quest Diagnostics Business Overview
- 12.2.3 Quest Diagnostics Revenue in Non-Invasive Prenatal Screening (NIPS) Business (2021-2026)
- 12.2.4 Quest Diagnostics Non-Invasive Prenatal Screening (NIPS) Product Portfolio
- 12.2.5 Quest Diagnostics Recent Developments
- 12.3 MedGenome
- 12.3.1 MedGenome Company Information
- 12.3.2 MedGenome Business Overview
- 12.3.3 MedGenome Revenue in Non-Invasive Prenatal Screening (NIPS) Business (2021-2026)
- 12.3.4 MedGenome Non-Invasive Prenatal Screening (NIPS) Product Portfolio
- 12.3.5 MedGenome Recent Developments
- 12.4 Mayo Clinic Laboratories
- 12.4.1 Mayo Clinic Laboratories Company Information
- 12.4.2 Mayo Clinic Laboratories Business Overview
- 12.4.3 Mayo Clinic Laboratories Revenue in Non-Invasive Prenatal Screening (NIPS) Business (2021-2026)
- 12.4.4 Mayo Clinic Laboratories Non-Invasive Prenatal Screening (NIPS) Product Portfolio
- 12.4.5 Mayo Clinic Laboratories Recent Developments
- 12.5 SYNLAB
- 12.5.1 SYNLAB Company Information
- 12.5.2 SYNLAB Business Overview
- 12.5.3 SYNLAB Revenue in Non-Invasive Prenatal Screening (NIPS) Business (2021-2026)
- 12.5.4 SYNLAB Non-Invasive Prenatal Screening (NIPS) Product Portfolio
- 12.5.5 SYNLAB Recent Developments
- 12.6 Veritas Genetics
- 12.6.1 Veritas Genetics Company Information
- 12.6.2 Veritas Genetics Business Overview
- 12.6.3 Veritas Genetics Revenue in Non-Invasive Prenatal Screening (NIPS) Business (2021-2026)
- 12.6.4 Veritas Genetics Non-Invasive Prenatal Screening (NIPS) Product Portfolio
- 12.6.5 Veritas Genetics Recent Developments
- 12.7 GGA
- 12.7.1 GGA Company Information
- 12.7.2 GGA Business Overview
- 12.7.3 GGA Revenue in Non-Invasive Prenatal Screening (NIPS) Business (2021-2026)
- 12.7.4 GGA Non-Invasive Prenatal Screening (NIPS) Product Portfolio
- 12.7.5 GGA Recent Developments
- 12.8 Cordlife
- 12.8.1 Cordlife Company Information
- 12.8.2 Cordlife Business Overview
- 12.8.3 Cordlife Revenue in Non-Invasive Prenatal Screening (NIPS) Business (2021-2026)
- 12.8.4 Cordlife Non-Invasive Prenatal Screening (NIPS) Product Portfolio
- 12.8.5 Cordlife Recent Developments
- 12.9 BGI Genomics
- 12.9.1 BGI Genomics Company Information
- 12.9.2 BGI Genomics Business Overview
- 12.9.3 BGI Genomics Revenue in Non-Invasive Prenatal Screening (NIPS) Business (2021-2026)
- 12.9.4 BGI Genomics Non-Invasive Prenatal Screening (NIPS) Product Portfolio
- 12.9.5 BGI Genomics Recent Developments
- 12.10 Berry Genomics
- 12.10.1 Berry Genomics Company Information
- 12.10.2 Berry Genomics Business Overview
- 12.10.3 Berry Genomics Revenue in Non-Invasive Prenatal Screening (NIPS) Business (2021-2026)
- 12.10.4 Berry Genomics Non-Invasive Prenatal Screening (NIPS) Product Portfolio
- 12.10.5 Berry Genomics Recent Developments
- 12.11 Annaroad
- 12.11.1 Annaroad Company Information
- 12.11.2 Annaroad Business Overview
- 12.11.3 Annaroad Revenue in Non-Invasive Prenatal Screening (NIPS) Business (2021-2026)
- 12.11.4 Annaroad Non-Invasive Prenatal Screening (NIPS) Product Portfolio
- 12.11.5 Annaroad Recent Developments
- 12.12 Genesky
- 12.12.1 Genesky Company Information
- 12.12.2 Genesky Business Overview
- 12.12.3 Genesky Revenue in Non-Invasive Prenatal Screening (NIPS) Business (2021-2026)
- 12.12.4 Genesky Non-Invasive Prenatal Screening (NIPS) Product Portfolio
- 12.12.5 Genesky Recent Developments
- 12.13 Weihansi Biomedical Technology
- 12.13.1 Weihansi Biomedical Technology Company Information
- 12.13.2 Weihansi Biomedical Technology Business Overview
- 12.13.3 Weihansi Biomedical Technology Revenue in Non-Invasive Prenatal Screening (NIPS) Business (2021-2026)
- 12.13.4 Weihansi Biomedical Technology Non-Invasive Prenatal Screening (NIPS) Product Portfolio
- 12.13.5 Weihansi Biomedical Technology Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst